University of Wisconsin–Madison

Chorom Pak, MCP Alumnus, Finalist in Governor’s Business Plan Contest

Lynx Biosciences is developing technology to predict how multiple myeloma and other blood cancers will respond to drug treatment, with tests designed to select the drug most likely to benefit a patient. Lynx analyzes a patient’s tumor cells alongside their bone-marrow cells, which influence the tumor cells’ susceptibility and resistance to cancer drugs. The assay uses a miniaturized device developed in collaboration with David Beebe in the UW–Madison Department of Biomedical Engineering. Lynx founder Chorom Pak, who has a doctorate in Molecular and Cellular Pharmacology from UW–Madison, adds that the Lynx approach measures tumor cell survival and can potentially be developed alongside any drug. See more here.